Syndeio debuts with $90 million and a synapse-first approach
US biotech Syndeio Biosciences has launched with over $90 million in funding and a pipeline of synapse-targeting neurotherapies aimed at treating major depressive disorder, Alzheimer’s disease, and other central nervous system (CNS) conditions.
Backed by a syndicate of life science investors including Catalio Capital Management, Innoviva, Tenmile, Luson Bioventures, and Palo Santo, Syndeio also lists AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) as strategic shareholders.
The company’s lead candidate, zelquistinel, is currently enrolling a Phase II study in major depressive disorder and is expected to enter a first-of-its-kind biomarker-driven trial in Alzheimer’s disease later this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze